Search

everythinglearnresearchcommunity

for

Search:↓

The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Early combination therapy can effectively regrow hair in frontal fibrosing alopecia.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

New compounds were made that are promising for prostate cancer therapy.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

Antiandrogens like flutamide are effective in treating conditions like prostate cancer and hair loss, but there's a need for more potent versions. Understanding their structure can help develop better treatments.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.